Author  
Place of duty  
Title   술후 항암요법에 따른 위암환자의 5 년 생존율에 관한 임상적 연구 ( A Clinical Study of 5 - Year Survival Rate of Stomach Cancer According to Postoperative Anticancer Chemotherapy )
Publicationinfo   1992 Jan; 024(01): 140-149.
Key_word   Stomach cancer, Survival rate, Anticancer chemotherapy
Full-Text  
Abstract   The gastric cancer is the most common malignancy in Korean and the number of them is seemed to be increasing every year. We could made a clinical analysis of 492 cases of the gas- tric cancer which were operated in the Dept. of Surgery, Kyung Hee University Hospital from January, 1979 to April, 1986. The results were as follows: 1) The age was from 17 years to 78 years old. Peak age incidence was 6th decade(28.9%), the mean age was 52.6 years and the ratio of male to female was 1.8: l. 2) Clinical symptoms, in order of frequency, were epigastric pain(40.2%), weight loss(35.0%), nausea(16.3%) and vomiting(15.4%). On physical examination, epigastric tenderness(39.0%) and palpable abdominal mass(18.3%) were common. 3) Preoperatively, 376 cases(76.4%) were seemed to be resectable and 42 cases(8.5%) were early gastric cancer. But postoperatively, 399 cases(81.1%) were curatively resectable and 90 cases(18.3%) wer early gastric cancer. 4) Distribution of the primary lesion, in order of frequency, wer antrum(71.5%), body(20.5%) and cardia-fudus(8.0%). 5) In TMN staging of the lesion, stage I was 60 cases(12.2%), stage III 64 cases(13.0%), stage III 24Z cases(49.2%) and stage IV 126 cases(25.6%). 6) The operative procedure were radical subtotal gastrectomy(69.1%), total gastrectomy(12.0%), palliative resection(4.9%), bypass operation(10.4%) and biopsy only(3.6%). 7) The postoperative complications were developed in 124 cases(15.2%) and common complications were pulmonary complications, wound infection, intraabdominal abscess and enterocu- taneous fistula, in order of frequency. 8) The ovrall operative mortality was 2.4%(12/492). 9) Tho overall 5-year survival rate of all gastric cancer patients was 53.8/ and stage I was 94. 9%, stage II 81.4%, stage III 52.1% and stage IV 14.9%. 1O) In stage II, 5-year survival rate was 75.9% in none chemotherapy group, 71.4% in MPC group and 91.3% in FAM group(statistically insignificant). In stage III, 5-year survival rate was 37% in none chemotherapy group, 45.9% in MFC group and 60.3% in FAM group(statistically significant). In stage IV, statistical significancy was showed between none chemotherapy group and FAM group(8.5% vs. 23.5%).
저 자   주흥재(Byong Ho Chin),이희수(Hee Soo Lee),이태석(Tae Seok Lee)